Role of cytokines in the treatment of acute leukemias: A review

Leukemia

Volumn 20, Issue 4, 2006, Pages 563-571

  Ravandi, F ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute leukemia; Clinical trials; G CSF; GM CSF

Indexed keywords

AMG 531; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CYTARABINE; CYTOKINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; IDARUBICIN; INTERLEUKIN 11; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN DERIVATIVE; MITOXANTRONE; PALIFERMIN; PLACEBO; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; THROMBOPOIETIN; TIOGUANINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL STIMULATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYTOPENIA; DISEASE DURATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG PULSE THERAPY; DRUG SAFETY; DRUG SENSITIVITY; FATIGUE; FEVER; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; INCIDENCE; INJECTION SITE REACTION; LEUKEMIA CELL; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK REDUCTION; SEPSIS; STOMATITIS; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; VASCULAR DISEASE;

EID: 33646475599     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404152     Document Type: Review

References (92)

1. Schiffer CA. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 1996; 88: 3675-3685.
2. Geller RB. Use of cytokines in the treatment of acute myelocytic leukemia: A critical review. J Clin Oncol 1996; 14: 1371-1382.
3. Estey EH. Growth factors in acute myeloid leukemia. Best Pract Res Clin Haematol 2001; 14: 175-187.
4. Rowe JM, Liesveld JL. Hematopoietic growth factors in acute leukemia. Leukemia 1997; 11: 328-341.
5. Schiffer CA. Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia. N Engl J Med 2003; 349: 727-729.
6. Miyauchi J, Kelleher CA, Wang C, Minkin S, MCculloch EA. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 1989; 73: 1272-1278.
7. Cannistra SA, Groshek P, Griffin JD. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 1989; 3: 328-334.
8. Bhalla K, Holladay C, Arlin Z, Grant S, Ibrado AM, Jasiok M. Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts. Blood 1991; 78: 2674-2679.
9. te Boekhorst PA, Lowenberg B, Vlastuin M, Sonneveld P. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia 1993; 7: 1191-1198.
10. Inatomi Y, Toyama K, Clark SC, Shimizu K, Miyauchi J. Combinations of stem cell factor with other hematopoietic growth factors enhance growth and sensitivity to cytosine arabinoside of blast progenitors in acute myelogenous leukemia. Cancer Res 1994; 54: 455-462.
11. Hiddemann W, Kiehl M, Zuhlsdorf M, Busemann C, Schleyer E, Wormann B et al. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia. Semin Oncol 1992; 19 (Suppl 4): 31-37.
12. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulmann P et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995; 332: 1671-1677.
13. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457-462.
14. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 1995; 332: 1678-1683.
15. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest oncology group study (9031). Blood 1998; 91: 3607-3615.
16. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin, Papa G et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997; 90: 4710-4718.
17. Bradstock K, Matthews J, Young G, Lowenthal R, Baxter H, Arthur C et al. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. Leukemia 2001; 15: 1331-1338.
18. Usuki K, Urabe A, Masaoka T, Ohno R, Mizoguchi H, Hamajima N et al. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: A multicentre randomized study. Br J Haematol 2002; 116: 103-112.
19. Goldstone AH, Burnett AK, Wheatley K, Snith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1302-1311.
20. Harousseau JL, Witz B, Lioure B, Hunault-Berger M, Desablens B, Desablens B et al. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: Results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol 2000; 18: 780-787.
21. Lowenberg B, Boogaerts MA, Daenen SM, Verhoef GE, Hagenbeek A, Vellenga E et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997; 15: 3496-3506.
22. Moore JO, Dodge RK, Amrein PC, Kolitz J, Lee EJ, Powell B et al. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood 1997; 89: 780-788.
23. Zittoun R, Suciu S, Mandelli F, de Witte T, Thaler J, Stryckmans P et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996; 14: 2150-2159.
24. Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: Final results of AML-13, a randomized phase-3 study. Blood 2005; 106: 27-34.
25. Bennett CL, Hynes D, Godwin J, Stinson TJ, Golub RM, Appelbaum FR. Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial. Cancer Invest 2001; 19: 603-610.
26. Bennett CL, Stinson TJ, Tallman MS, Stadtmauer EA, Marsh RW, Friedenberg W et al. Economic analysis of a randomized placebo-controlled phase III study of granulocyte-macrophage colony stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490). Ann Oncol 1999; 10: 177-182.
27. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.
28. Cannistra SA, DiCarlo J, Groshek P, Kanakura Y, Berg D, Mayer RJ et al. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 1991; 5: 230-238.
29. Witz F, Sadoun A, Perrin MC, Berthou C, Briere J, Cahn JY et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1998; 91: 2722-2730.
30. Lowenberg B, van Putten W, Theobald M, Gmur J, Verdonck L, Sonneveld S et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003; 349: 743-752.
31. Lofgren C, Paul C, Astrom M, Hast R, Hedenius M, Lerner R et al. Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukemia: A Swedish multicentre randomized trial. Br J Haematol 2004; 124: 474-480.
32. Lowenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GE, Vellenga E et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 1997; 90: 2952-2961.
33. Heil G, Chadid L, Hoelzer D, Seipelt G, Mitrou P, Huber C et al. GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia 1995; 9: 3-9.
34. Hast R, Hellstrom-Lindberg E, Ohm L, Bjorkholm M, Celsing F, Dahl IM et al. No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: Better outcome in patients with less proliferative disease. Leukemia 2003; 17: 1827-1833.
35. Uyl-de Groot CA, Lowenberg B, Vellenga E, Suciu S, Willemze R, Rutten FF et al. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. Br J Haematol 1998; 100: 629-636.
36. Ohno R, Naoe T, Kanamaru A, Yoshida M, Hiraoka A, Kobayashi T et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 1994; 83: 2086-2092.
37. Thomas X, Fenaux P, Dombret H, Delair S, Dreyfus F, Tilly H et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: A multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia 1999; 13: 1214-1220.
38. Rossi HA, O'Donnell J, Sarcinelli F, Stewart FM, Quesenberry PJ, Becker PS. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2002; 16: 310-315.
39. He XY, Pohlman B, Lichtin A, Rybicki L, Kalaycio M. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia. Leukemia 2003; 17: 1078-1084.
40. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: A trial by the Eastern Cooperative Oncology Group. Blood 2004; 103: 479-485.
41. Jahns-Streubel G, Reuter C, Auf der Landwehr U, Unterhalt M, Schleyer E, Wormann B et al. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Blood 1997; 90: 1968-1976.
42. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukemia-current status and future perspectives. Lancet Oncol 2001; 2: 597-607.
43. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003; 98: 1337-1354.
44. Hoelzer D, Gokbuget N. Recent approaches in acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol 2000; 36: 49-58.
45. Kantarjian HM, Estey E, O'Brien S, Anaissie E, Beran M, Pierce S et al. Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission. Cancer 1993; 72: 2950-2955.
46. Bassan R, Lerede T, Di Bona E, Rossi G, Pogliani E, Rambaldi A et al. Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: Effects, role of patient pretreatment characteristics, and costs. Leuk Lymphoma 1997; 26: 153-161.
47. Ottmann OG, Ganser A, Freund M, Heil G, Hiddenmann W, Heit W et al. Simultaneous administration of granulocyte colony-stimulating factor (Filgrastim) and induction chemotherapy in acute lymphoblastic leukemia. A pilot study. Ann Hematol 1993; 67: 161-167.
48. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547-561.
49. Welte K, Reiter A, Mempel K, Pfetsch M, Schwab G, Schrappe M et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group. Blood 1996; 87: 3143-3150.
50. Laver J, Amylon M, Desai S, Link M, Schwenn M, Mahmoud H et al. Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: A Pediatric Oncology Group pilot study. J Clin Oncol 1998; 16: 522-526.
51. Clarke V, Dunstan FD, Webb DK. Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia. Med Pediatr Oncol 1999; 32: 331-335.
52. Michel G, Landman-Parker J, Auclerc MF, Mathey C, Leblanc T, Legall E et al. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: A randomized trial in very high-risk childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 1517-1524.
53. Little MA, Morland B, Chisholm J, Hole A, Shankar A, Devine T et al. A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Med Pediatr Oncol 2002; 38: 98-103.
54. Heath JA, Steinherz PG, Altman A, Sather H, Jhanwar S, Halpern S et al. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: A Children's Cancer Group Study. J Clin Oncol 2003; 21: 1612-1617.
55. Pui CH, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997; 336: 1781-1787.
56. Ottmann OG, Hoelzer D, Gracien E, Ganser A, Kelly K, Reutzel R et al. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: A randomized phase III trial. Blood 1995; 86: 444-450.
57. Ohno R, Tomonaga M, Ohshima T, Masaoka T, Asou N, Oh H et al. A randomized controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. Japan Adult Leukemia Study Group. Int J Hematol 1993; 58: 73-81.
58. Geissler K, Koller E, Hubmann E, Niederwieser D, Hinterberger W, Geissler D et al. Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia-a randomized phase-III study. Blood 1997; 90: 590-596.
59. Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998; 92: 1556-1564.
60. Ifrah N, Witz F, Jouet JP, Francois S, Lamy T, Linassier C et al. Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. GOELAMS Group. Cancer Oct 15; 1999: 86 (8):1496-1505.
61. Holowiecki J, Giebel S, Krzemien S, Krawczyk-Kulis M, Jagoda K, Kopera M et al. G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: A randomized multicenter study. Leuk Lymphoma 2002; 43: 315-325.
62. Delorme J, Badin S, Le Corroller AG, Auvrignon AA, Auclere MF, Gandemer V et al. Economic evaluation of recombinant human granulocyte colony-stimulating factor in very high-risk childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2003; 25: 441-447.
63. Lotzova E, Savary CA, Herberman RB. Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. Leuk Res 1987; 11: 1059-1066.
64. Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M et al. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 1986; 68: 938-948.
65. Margolin K, Forman SJ. Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy. Cancer J Sci Am 2000; 6 (Suppl 1): S33-S38.
66. Foa R, Meloni G, Tosti S, Novarino A, Fenu S, Gavosto F et al. Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: A pilot study. Br J Haematol 1991; 77: 491-496.
67. Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994; 84: 2158-2163.
68. Meloni G, Vignetti M, Pogliani E, Invernizzi R, Allione B, Mirto S et al. Interleukin-2 therapy in relapsed acute myelogenous leukemia. Cancer J Sci Am 1997; 3 (Suppl 1): S43-S47.
69. Goodman M, Cabral L, Cassileth P. Interleukin-2 and leukemia. Leukemia 1998; 12: 1671-1675.
70. Bergmann L, Heil G, Kolbe K, Lengfelder E, Puzicha E, Martin H et al. Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia. Leuk Lymphoma 1995; 16: 271-279.
71. Meloni G, Vignetti M, Andrizzi C, Capria S, Foa R, Mandelli F. Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: Updated experience with 20 cases. Leuk Lymphoma 1996; 21: 429-435.
72. Soiffer RJ, Murray C, Cochran K, Cameron C, Wang E, Schow PW et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 1992; 79: 517-526.
73. Soiffer RJ, Murray C, Gonin R, Ritz J. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 1994; 84: 964-971.
74. Klingemann HG, Phillips GL. Is there a place for immunotherapy with interleukin-2 to prevent relapse after autologous stem cell transplantation for acute leukemia? Leuk Lymphoma 1995; 16: 397-405.
75. Robinson N, Sanders JE, Benyunes MC, Beach K, Lindgren C, Thompson JA et al. Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood 1996; 87: 1249-1254.
76. Blaise D, Attal M, Pico JL, Reiffers J, Stoppa AM, Bellanger C et al. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. Leuk Lymphoma 1997; 25: 469-478.
77. Attal M, Blaise D, Marit G, Payen C, Michallet M, Vernant JP et al. Consolidation treatment of adult acute lymphoblastic leukemia: A prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group Blood 1995; 86: 1619-1628.
78. Cortes JE, Kantarjian HM, O'Brien S, Giles F, Keating MJ, Freireich EJ et al. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer 1999; 85: 1506-1513.
79. Farag SS, George SL, Lee EJ, Baer M, Dodge RK, Becknell B et al. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin Cancer Res 2002; 8: 2812-2819.
80. Sievers EL, Lange BJ, Sondel PM, Krailo MD, Gan J, Liu-Mares W et al. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: A report from the Children's Cancer Group. J Clin Oncol 1998; 16: 914-919.
81. Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000; 95: 2530-2535.
82. Archimbaud E, Ottmann OG, Yin JA, Lechner K, Dombret H, Sanz MA et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999; 94: 3694-3701.
83. Basser RL, O'Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002; 99: 2599-2602.
84. Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: Comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002; 99: 4343-4349.
85. Ellis M, Zwaan F, Hedstrom U, Poynton C, Kristensen J, Jumaa P et al. Recombinant human interleukin 11 and bacterial infection in patients with [correction of] haematological malignant disease undergoing chemotherapy: A double-blind placebo-controlled randomised trial. Lancet 2003; 361: 275-280.
86. Wielenga JJ, Vellenga E, Groenewegen A, Sonneveld P, Lowenberg B. Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): A phase I/II study. Leukemia 1996; 10: 43-47.
87. Zwierzina H, Suciu S, Loeffler-Ragg J, Neuwirtova R, Fenaux P, Beksac M et al. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia 2005; 19: 1929-1933.
88. Rubin JS, Osada H, Finch PW, Taylor WG, Rudikoff S, Aaronson SA. Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci USA 1989; 86: 802-806.
89. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590-2598.
90. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76: 628-638.
91. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999; 93: 2478-2484.
92. Buchner T, Berdel WE, Hiddemann W. Priming with granulocyte colony-stimulating factor - relation to high-dose cytarabine in acute myeloid leukemia. N Engl J Med 2004; 350: 2215-2216.